Amiodarone and thyroid health in arrhythmia care

Amiodarone remains an important antiarrhythmic medicine for atrial fibrillation, ventricular tachycardia and other difficult rhythm disorders. Its effectiveness reflects complex effects on sodium, potassium and calcium channels, as well as adrenergic activity. The same pharmacology is accompanied by a substantial iodine load and long tissue half-life, creating a continuing risk of thyroid dysfunction during treatment and for months after it is stopped.

Amiodarone-induced thyroid dysfunction may present as hypothyroidism or thyrotoxicosis, with symptoms that overlap with heart failure, recurrent arrhythmia and medication toxicity. A structured plan for baseline assessment, laboratory surveillance and specialist escalation helps clinicians protect rhythm control without overlooking a treatable endocrine complication. In Australia, this plan also needs to fit real-world access to Medicare-funded pathology, local endocrinology services and Therapeutic Goods Administration (TGA) prescribing information.

Why amiodarone changes thyroid physiology

Amiodarone contains approximately 37% iodine by weight, and its metabolism releases a large quantity of iodine into the circulation. It also inhibits peripheral conversion of thyroxine (T4) to triiodothyronine (T3), alters thyroid hormone transport and can have direct cytotoxic effects on thyroid tissue. Consequently, free T4 may rise and T3 may fall without genuine thyroid disease, particularly early in therapy.

The thyroid usually adapts through the Wolff–Chaikoff effect, temporarily reducing hormone synthesis after an iodine load. Some patients escape this effect and develop iodine-induced hormone excess, often termed type 1 amiodarone-induced thyrotoxicosis. This is more likely in people with multinodular goitre or latent Graves disease. Type 2 disease is a destructive thyroiditis in a previously normal gland, causing the release of stored hormone. Mixed forms are common, and the distinction may not be clear at first assessment.

Amiodarone is frequently prescribed when the consequences of recurrent arrhythmia are serious. Decisions about continuing it should therefore be made with the rhythm team rather than in isolation. Evidence from other rhythm-management strategies, including device outcome data, can help frame broader discussions about appropriate therapy, but an implantable device does not replace treatment of an active thyroid disorder.

Who is at risk

A personal or family history of thyroid disease, positive thyroid peroxidase antibodies, multinodular goitre, Graves disease and older age increase the likelihood of amiodarone-related thyroid problems. Women and people with pre-existing autoimmune disease may also warrant particular attention. A normal TSH before treatment reduces immediate concern but does not eliminate the possibility of later dysfunction.

Clinical risk is influenced by the reason for prescribing amiodarone. A patient with recurrent ventricular tachycardia may have little flexibility to stop therapy, while a patient using it for intermittent atrial fibrillation may have alternative rhythm or rate-control options. Renal function does not determine amiodarone clearance in the same way as many other medicines, but frailty, polypharmacy and cardiac reserve affect how well a patient tolerates thyroid hormone excess or deficiency.

Australian clinicians should review the local product information through the TGA and account for iodine exposure from contrast-enhanced CT, supplements and some complementary medicines. Iodine-containing kelp products are available in Australian health-food and online markets and can complicate thyroid assessment. Asking specifically about these products is more reliable than relying on a generic medication list.

A practical monitoring pathway

Before starting amiodarone, record symptoms, pulse, weight and neck examination, then obtain TSH and free T4. Free T3 can provide a useful baseline when thyrotoxicosis is suspected or when results are difficult to interpret. Thyroid peroxidase antibodies, thyroglobulin antibodies and thyroid ultrasound are not mandatory for every patient, but they are valuable when there is a goitre, autoimmune history or an abnormal baseline result.

Repeat thyroid function tests at about three months after initiation and then every six months while treatment continues, with earlier testing if symptoms develop. TSH is generally the best screening test, interpreted alongside free T4 and the clinical picture. During the first several months, TSH can be transiently abnormal, while the characteristic amiodarone effect may produce a mildly high free T4 and low-normal T3 without clinically significant thyrotoxicosis.

A practical Australian pathway can be coordinated between the cardiologist, general practitioner and pathology provider. Medicare-funded pathology makes scheduled surveillance accessible in metropolitan areas such as Sydney, Melbourne and Brisbane, while patients in regional or remote communities may need blood collection timed with cardiology or telehealth appointments. Documenting the next test date in the shared care plan reduces missed monitoring when prescriptions are renewed by different clinicians.

Recognising and treating hypothyroidism

Amiodarone-associated hypothyroidism often develops gradually. Fatigue, cold intolerance, constipation, dry skin, weight gain, bradycardia and cognitive slowing can be mistaken for ageing, heart failure or depression. A raised TSH with a low free T4 supports overt hypothyroidism. Subclinical disease is characterised by raised TSH with free T4 within the reference range, although interpretation should consider symptoms, antibody status and cardiovascular risk.

Levothyroxine is the usual treatment for overt hypothyroidism. Amiodarone can often be continued when it provides important rhythm protection, particularly because stopping it does not promptly remove the iodine or drug effect. The levothyroxine dose should be increased cautiously in people with ischaemic heart disease, older adults and patients with ventricular arrhythmias, with repeat TSH and free T4 after an appropriate interval.

A modest TSH elevation without symptoms may be monitored rather than treated immediately, especially early after amiodarone begins. Persistent or marked TSH elevation, positive antibodies, goitre or clear symptoms shifts the balance towards replacement. Treatment targets should be individualised; aggressive normalisation may provoke angina, atrial fibrillation or other arrhythmias in vulnerable patients.

Managing amiodarone-induced thyrotoxicosis

Thyrotoxicosis may appear as palpitations, tremor, heat intolerance, weight loss, anxiety, diarrhoea or insomnia, but some cardiac patients present mainly with worsening atrial fibrillation, heart failure or ventricular ectopy. Obtain TSH, free T4 and free T3 promptly, and assess severity with an ECG, examination and cardiac review. Severe heart failure, hypotension, delirium or rapidly deteriorating arrhythmia requires urgent hospital management.

Type 1 disease is generally treated with a thionamide such as carbimazole, while type 2 disease responds more reliably to corticosteroids because the mechanism is destructive thyroiditis. Mixed disease may require both approaches. Thyroid ultrasound with colour-flow Doppler, antibody testing and the clinical context can help, although isotope uptake studies are often difficult to interpret after iodine-rich amiodarone exposure. Endocrinology involvement is appropriate whenever the diagnosis is uncertain or the patient is clinically unstable.

Stopping amiodarone is not automatically beneficial. Its prolonged half-life means thyroid toxicity may continue after withdrawal, while stopping can remove essential protection from life-threatening arrhythmia. The decision should involve electrophysiology and endocrinology, with alternatives such as catheter ablation, another antiarrhythmic or a device-based strategy considered according to the underlying rhythm and ventricular function. Corticosteroids, thionamides and beta blockade require careful adjustment in diabetes, pulmonary disease, hypotension and heart failure.

Refractory thyrotoxicosis may require thyroidectomy, particularly when rapid control is essential or medication is ineffective. Radioactive iodine is often unsuitable during the iodine-loaded state because uptake may be low. In Australia, access to endocrine surgery and nuclear medicine varies between major centres and regional areas, so early referral is preferable to waiting for medical treatment to fail.

Integrating thyroid care with rhythm strategy

Thyroid dysfunction can destabilise atrial fibrillation, increase ventricular ectopy and worsen myocardial oxygen demand. Correcting the biochemical abnormality is therefore part of arrhythmia management rather than a separate administrative task. Review anticoagulation when atrial fibrillation changes, because restoration of sinus rhythm or progression to persistent arrhythmia may alter stroke-risk discussions, although thyroid treatment does not replace standard risk assessment.

Patients should receive clear advice about symptoms that need prompt review, including sustained rapid pulse, chest pain, breathlessness, syncope, marked weakness, new confusion or sudden weight change. Explain that thyroid blood tests may remain abnormal after amiodarone is discontinued. This prevents false reassurance and supports continued surveillance during the prolonged elimination phase.

All clinicians prescribing or renewing amiodarone should record the indication, intended duration, baseline thyroid results and next monitoring date. The broader evidence base can be followed through the journal’s arrhythmia research archive, including work on electrophysiology, ablation and implantable devices that may inform future alternatives. In Australia, communication between hospital services, general practices and community pharmacies is particularly important when a patient moves between metropolitan and rural care.

Use a written monitoring schedule, interpret thyroid tests in the context of amiodarone’s pharmacology, and escalate promptly when symptoms or results suggest thyrotoxicosis. Coordinated care between electrophysiology, endocrinology, general practice and pathology services allows clinicians to preserve essential rhythm treatment while addressing thyroid disease safely.